Clinical Trials Logo

Clinical Trial Summary

This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03277261
Study type Interventional
Source TG Therapeutics, Inc.
Contact
Status Completed
Phase Phase 3
Start date September 19, 2017
Completion date November 6, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04130997 - An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Phase 3
Completed NCT02921035 - Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
Terminated NCT04878211 - A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Phase 4
Recruiting NCT04086225 - Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon® Phase 1
Completed NCT03745144 - Effects of Cladribine Tablets on the PK of Microgynon® Phase 1
Active, not recruiting NCT04667949 - Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients Phase 4
Completed NCT03277248 - Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) Phase 3